Comparative efficacy and tolerability of a novel botanical formulation LI12507F in the treatment and control of obesity

ISRCTN ISRCTN52261953
DOI https://doi.org/10.1186/ISRCTN52261953
Secondary identifying numbers 10-002/Ob/Sp
Submission date
09/04/2010
Registration date
30/07/2010
Last edited
20/01/2014
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Artatrana Misra
Scientific

Department of General Medicine
Nagarjuna Hospital
Vijayawada
520007
India

Study information

Study designRandomised double blind placebo controlled study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleComparative efficacy and tolerability of a novel botanical formulation LI12507F in the treatment and control of obesity: a randomised, double-blind placebo controlled clinical study
Study acronymAnti-obese Nutraceuticals
Study objectivesSupplementation of herbal formulations might be useful for management of body weight in obese human subjects.
Ethics approval(s)Internal Review Board of ASR Academy of Medical Sciences (India) approved on the 10th March 2010 (ref: ASRIRB-10-002)
Health condition(s) or problem(s) studiedObesity
InterventionA total 60 human subjects is randomised and divided into two groups:
1. LI12507F
2. Placebo

The treatment dosage is 800 mg daily, consisting of two 400 mg doses daily for the active group. Each subject included in the second group receives matched placebo per day.

The study duration will be of 56 days. The visits and the evaluations are at the baseline, 14th day, 28th day and the 56th day.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)LI12507F
Primary outcome measure1. Physical/anthropometric parameters:
1.1. Body weight
1.2. Body mass index
1.3. Waist hip ratio
2. Biochemical parameters (serum/plasma):
2.1. Fasting glucose
2.2. Fasting insulin
2.3. Triglycerides
2.4. Cholesterol
2.5. High density lipoprotein (HDL) cholesterol
2.6. Low density lipoprotein (LDL) cholesterol

The primary and secondary outcomes will be measured on baseline, 14th day, 28th day and 56th day.
Secondary outcome measuresObesity biomarkers (serum/plasma):
1. Leptin
2. Adiponectin
3. Ghrelin

The secondary outcomes will be measured on the baseline, and on 56th day.
Overall study start date14/03/2010
Completion date10/08/2010

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participantsSixty participants
Key inclusion criteria1. Participants must understand the risks and benefits of the study
2. Adults ages 21 - 50 years, either sex
3. Body mass index (BMI) greater than 30 kg/m^2
4. Willingness to participate in an exercise-walking program, supervised by a trained exercise specialist
5. Willingness to consume the prescribed study diet of approximately 2,000 KCal per day as outlined in the protocol (meals will be provided at free of cost by the study sponsor)
6. Ability to provide written informed consent for participation in the trial
7. Willingness to complete standard health history questionnaire before induction into the study
8. Willingness to participate in 5 clinic visits (Screening, baseline, 2, 4 and 8 weeks)
9. Subject willing to participate in health exercise program (30 minutes walking) monitored by the study physical trainer
10. Subjects must be instructed to abstain from alcoholic products during the study
11. If female:
11.1. Should be negative in pregnancy test
11.2. Should not be nursing
11.3. Of childbearing potential, should agree to follow an acceptable method of birth control for the duration of the study, such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), etc., or postmenopausal for at least 1 year, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)
Key exclusion criteria1. History of thyroid disease or cardiovascular disease or diabetes (uncontrolled)
2. Subjects having chronic diarrhoeal disorders, cancer, neurological disorders, hepatic dysfunction
3. Respiratory tract infection and other serious medical respiratory illnesses (i.e., chronic obstructive pulmonary disease [COPD], sarcoidosis)
4. History of allergy to spices and herbal products
5. Intractable obesity or uncontrolled body weight, BMI greater than 40 kg/m^2
6. Non obese (BMI less than 30 kg/m^2) and morbidly obese (BMI greater than 40 kg/m^2)
7. Presently using other weight loss medications, as well as stimulants, laxatives or diuretics taken solely for the purpose of weight loss
8. Pregnant or nursing or lactating females
9. Recent, unexplained weight loss or gain
10. Women with a positive pregnancy test
11. Human immunodeficiency virus (HIV) or other known immunodeficiency
12. Undergone surgery before 30 days of screening or planning to undergo surgery within the study days
13. History of hepatitis, pancreatitis, lactic acidosis or hepatomegaly with steatosis
14. History of motor weakness or peripheral sensory neuropathy
15. Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations
Date of first enrolment14/03/2010
Date of final enrolment10/08/2010

Locations

Countries of recruitment

  • India

Study participating centre

Department of General Medicine
Vijayawada
520007
India

Sponsor information

Laila Nutraceuticals (India)
Industry

Unit-6 & 7
Phase-III
Jawahar Autonagar
Vijayawada
520007
India

ROR logo "ROR" https://ror.org/05q6g7072

Funders

Funder type

Industry

Laila Nutraceuticals (India)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/06/2013 Yes No